CAL
JANX icon

Capital Advisors Ltd’s Janux Therapeutics JANX Stock Holding History

Capital Advisors Ltd’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Buy
+8
New +$116 ﹤0.01% 1475
2022
Q4 		– Sell
-90
Closed -$1K – 1415
2022
Q3 		$1K Buy
+90
New +$1.2K ﹤0.01% 1042

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Capital Advisors Ltd's JANX Position: Q2 2026 in Review

Capital Advisors Ltd opened a new position in Janux Therapeutics (JANX) in Q2 2026: 8 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #1475 among its holdings. This is a return to the name: Capital Advisors Ltd previously reported a position in JANX as recently as Q3 2022.

Capital Advisors Ltd first reported a position in JANX in Q3 2022 and has held it in 2 quarters since. The position peaked at $1K in Q3 2022. 198 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Capital Advisors Ltd held 8 shares of Janux Therapeutics worth $0 as of Q2 2026.
  • Janux Therapeutics was a new Capital Advisors Ltd position in Q2 2026.
  • Janux Therapeutics made up ﹤0.01% of Capital Advisors Ltd's portfolio in Q2 2026, its #1475 holding.
  • Capital Advisors Ltd first reported a position in Janux Therapeutics in Q3 2022 and has held it in 2 quarters since.
  • Capital Advisors Ltd's Janux Therapeutics position peaked at $1K in Q3 2022.
  • 198 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Capital Advisors Ltd's 13F filing for Q2 2026, filed 16 Jul 2026.